Aurobindo Pharma Q4 FY25 Earnings Results: Revenue Rose 10.6% YOY to ₹8,382 Crore

Aurobindo Pharma Limited, headquartered in Hyderabad, announced its consolidated results for the quarter ending March 31, 2025. The company posted a 10.6% year-on-year growth in revenue from operations, reaching ₹8,382 crore. This growth was supported by a strong performance in its US and European markets.

Segment-Wise Revenue Performance

• US Formulations revenue rose 13.5% YoY to ₹4,072 crore (approx. USD 470 million), showing continued strength in the North American market.
• European Formulations posted a robust 17.2% YoY growth, generating ₹2,147 crore (EUR 236 million).
• ARV (Anti-Retroviral) revenue surged 29.4% YoY to ₹308 crore.
• API (Active Pharmaceutical Ingredients) segment grew 5.0% YoY to ₹1,069 crore.
• However, Growth Markets revenue declined 7.8% YoY to ₹786 crore (USD 91 million).

Aurobindo Pharma Q4 FY25 Earnings Results: Profitability and R&D Investments

The company achieved an EBITDA before R&D of ₹2,202 crore, with a strong margin of 26.3%. After accounting for R&D expenses and other adjustments, EBITDA stood at ₹1,792 crore with a margin of 21.4%. The net profit for the quarter was ₹903 crore, and the earnings per share (EPS) stood at ₹15.56. Aurobindo invested ₹423 crore in R&D, which accounts for 5% of its revenue, highlighting its commitment to product innovation.

USFDA Approvals Secured in Q4 FY25

1. Tretinoin Gel USP (0.01% and 0.025%) – Anti-Infective
2. Nystatin Cream USP (100,000 units/g) – Anti-Fungal
3. Azelastine Hydrochloride Nasal Spray (205.5 mcg, OTC) – Anti-Histamine
4. Pantoprazole Sodium for Delayed-Release Oral Suspension (40mg) – Gastrointestinal drug

Read More, ITC Final Divided Record Date on May 28: What It Means for Shareholders? 

About Aurobindo Pharma

Aurobindo Pharma is a global pharmaceutical firm with a presence in over 150 countries. The company manufactures generic and branded pharmaceuticals and APIs, with 30+ manufacturing units approved by global regulatory bodies like the USFDA, UK MHRA, WHO, and others. 

Aurobindo Pharma Share Price 

As of May 27, 2025, Aurobindo Pharma share price is trading at ₹1,197.00, having opened at ₹1,172.90 and reached a high of ₹1,207.70 and a low of ₹1,165.00 during the day. The company has a market capitalisation of ₹69,530 crore and a price-to-earnings (P/E) ratio of 20.01. It does not currently offer a dividend yield. Over the past 52 weeks, the stock has touched a high of ₹1,592.00 and a low of ₹1,010.00.

Conclusion

Aurobindo Pharma has delivered a strong Q4 FY25 performance, driven by international markets, strategic product development, and operational efficiency. With significant USFDA approvals and a consistent focus on innovation and capacity building, the company is well-positioned for long-term sustainable growth.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.      

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.